These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8549310

  • 1. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
    Molinari G, Schito GC.
    Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F, Peters G.
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of BAY Y 3118 against selected species.
    Verbist L, Verhaegen J.
    Drugs; 1995 Oct; 49 Suppl 2():264-5. PubMed ID: 8549326
    [No Abstract] [Full Text] [Related]

  • 5. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE, Lindmark A, Persson I.
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [Abstract] [Full Text] [Related]

  • 6. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG, Jones RN.
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [Abstract] [Full Text] [Related]

  • 7. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
    Carlyn CJ, Doyle LJ, Knapp CC, Ludwig MD, Washington JA.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L, Suárez AI, Ortega MC, Perea EJ.
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS, Ahlén S.
    Chemotherapy; 1993 Jun; 39(1):32-5. PubMed ID: 8383030
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS, Nathan C, Hariharan R, Kostman JR, Kabins SA, Weinstein RA.
    Chemotherapy; 1996 Jun; 42(4):235-9. PubMed ID: 8804789
    [Abstract] [Full Text] [Related]

  • 14. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
    Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, Hurtado C, Blanco MT, Gómez-García AC.
    J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
    [No Abstract] [Full Text] [Related]

  • 15. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G, Prosser BL.
    Am J Med; 1993 Mar 22; 94(3A):2S-8S. PubMed ID: 8383919
    [Abstract] [Full Text] [Related]

  • 16. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL, Fuchs PC.
    J Chemother; 1997 Feb 22; 9(1):9-16. PubMed ID: 9106012
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of MF 5137, a new potent 6-aminoquinolone.
    Wise R, Pagella PG, Cecchetti V, Fravolini A, Tabarrini O.
    Drugs; 1995 Feb 22; 49 Suppl 2():272-3. PubMed ID: 8549329
    [No Abstract] [Full Text] [Related]

  • 18. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998 Feb 22; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 19. Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Sirgel FA, Venter A, Heilmann HD.
    J Antimicrob Chemother; 1995 Feb 22; 35(2):349-51. PubMed ID: 7759400
    [No Abstract] [Full Text] [Related]

  • 20. Antibiotic selective pressure and development of bacterial resistance.
    Kolár M, Urbánek K, Látal T.
    Int J Antimicrob Agents; 2001 May 22; 17(5):357-63. PubMed ID: 11337221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.